Corvus Pharmaceuticals Inc
Затворен
11.12 -4.71
Преглед
Промяна на цената на акция
24 ч
Минимум
11.03
Максимум
11.24
Приходи | -1.4M -14M |
|---|---|
EPS | -0.15 |
Служители | 37 |
EBITDA | -2.7M -15M |
Препоръки | Силна покупка |
|---|---|
12-месечна прогноза | +184.17% upside |
Следващи печалби | 6.08.2026 г. |
|---|
Пазарна капитализация | -331M 1B |
|---|---|
Предишно отваряне | 15.83 |
Предишно затваряне | 11.12 |
Corvus Pharmaceuticals Inc Графика
Миналото представяне не гарантира бъдещи резултати.
Свързани новини
Сравнение с други в отрасъла
Ценова промяна
Corvus Pharmaceuticals Inc Прогноза
Ценова цел
By TipRanks
184.17% нагоре
12-месечна прогноза
Среден 31.6 USD 184.17%
Висок 40 USD
Нисък 27 USD
Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за Corvus Pharmaceuticals Inc през последните три месеца.
Финанси
Продажбени и админисративни разходи
Оперативни разходи
Печалба преди облагане с данъци
Продажби
Разходи за продажби
Брутна печалба от продажби
Разходи за лихви по дълг
EBITDA
Оперативна печалба
$
Относно Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
